audeo indicative ipo pricing is now public, page-26

"The primary endpoint will be reached when 350 patients have experienced disease progression or death, which it is anticipated in the second half of 2013."

If one had to choose a cancer to have, this is not a good one to choose.

Progression-free survival for irinotecan averaged 2.4 months in our phase 2. If enrollment is completed close to year end, there will be enough data long before the second half of 2013. The "second half" is actually being cautious, but that's a good thing. The stronger information one gathers the better one can prove efficacy (and gain fda approval).